Abstract Body

Background: HIV pre-exposure prophylaxis (PrEP) trials with tenofovir-containing regimens have achieved perfect protection in some sub-populations and no benefit in others. Pharmacological data from all PrEP trials and smaller pharmacokinetically (PK)-intensive studies provide critically useful data to help understand the larger sources of PrEP trial outcome variability, principally, highly variable adherence across studies. There is a clear concentrationresponse relationship between tenofovir and its protective benefit that indicates PrEP regimens are highly effective, if taken as directed. Clinical PrEP implementation questions remain, especially questions of intermittent or periodic dosing regimens that have not and may not be formally studied in the future. In the absence of prospective randomized trials, clinical pharmacology provides some cautious guidance on the limitations of intermittent or periodic PrEP dosing which may differ in its protective effect for receptive anal and vaginal intercourse. In this regard, animal and ex vivoHIV challenge studies may also be useful, but with important caveats. Looking forward, this rich pharmacological datashould inform planning the next generation of PrEP trials. Conclusions: Clinical pharmacology helps explain PrEP trial outcomes, inform PrEP management in the clinic, and guide the design of the next generation of PrEP candidates.